All News Top News Nov 19, 2019 Teva Announces Successful Upsize of Senior Notes Offering and Pricing of $2.1 Billion of Senior Notes Learn More Share Top News Nov 8, 2019 Teva Announces $1.5 Billion Debt Tender Offers Learn More Share Top News Nov 8, 2019 Teva Announces Launch of $1,500,000,000 Offering of Senior Notes Learn More Share Top News Nov 7, 2019 Teva and Celltrion Announce the Availability of TRUXIMA® (rituximab-abbs) Injection, the First Biosimilar to Rituxan® (rituximab) in the United States Learn More Share Top News Nov 7, 2019 Teva Announces Appointment of New Chief Financial Officer Learn More Share
Top News Nov 19, 2019 Teva Announces Successful Upsize of Senior Notes Offering and Pricing of $2.1 Billion of Senior Notes Learn More
Top News Nov 7, 2019 Teva and Celltrion Announce the Availability of TRUXIMA® (rituximab-abbs) Injection, the First Biosimilar to Rituxan® (rituximab) in the United States Learn More